Oguchi et al. trialed TAS2940, a novel, irreversible pan-ErbB inhibitor with remarkable brain penetration, in generic cell lines and intracranial mouse xenograft cancer models, demonstrating inhibition of tumor growth against cells with HER2 amplification and EGFRvIII mutation and improving the survival of subjects, indicating its therapeutic potential for glioblastoma with EGFR mutations [127]. The gene discussed is EGFR; the disease is neoplasm.